explore -WSS

explore

author：entertainment 2025-09-27 13:09:39 - browse：1

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： New menopause drug shows promise in relief for hot flashes

WSS

Care demand spikes challenge UnitedHealth’s provider arm

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Heart disease and mental health: A look at cardiac psychology

Mike Pence clashes with Tucker Carlson in Iowa

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Idaho abortion case may prompt more restrictions in other states

Wikipedia

explore

entertainment

Apple is now the first public company to be valued at $3 trillion

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

State Dept. review finds Biden bears some blame for Afghanistan failures

Celiac disease study examines precisely how gluten triggers injury

The cancer drug shortage isn’t new — and neither are the solutions

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

In age of alternative facts, a scholarly course on calling out crap

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

focus

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Can CDC director Mandy Cohen drive consensus in Washington?

Europe sees delivery challenges ahead on Alzheimer's therapies

Biotech reporter’s notebook: A sunnier mood at JPM 2024

hotspot

hotspot

hotspot

explore